Read OSN’s Sept. 10 publication exclusives online

The cover story in the Sept. 10, 2018, issue of Ocular Surgery News focused on retinal toxicity stemming from hydroxychloroquine dosing. Here are a few of the issue’s publication exclusives.

Cover story

Despite Plaquenil dosing recommendations, retinal toxicity remains

The American Academy of Ophthalmology has published several dosing and screening recommendations for hydroxychloroquine to avoid potential retinal toxicity, yet some patients still experience permanent vision loss resulting from hydroxychloroquine retinopathy due to improper dosing of the drug and improper screening. Read more.

Lindstrom’s Perspective

Ophthalmologists play important role for patients treated with hydroxychloroquine

Hydroxychloroquine has been used in American medicine since 1955. It is primarily prescribed to treat chloroquine-sensitive malaria, rheumatoid arthritis, lupus erythematosus, porphyria cutanea tarda and post-Lyme disease arthritis. It is an anti-inflammatory that interferes with toll-like receptors, especially toll-like receptor 9, reducing the activation of plasmacytoid dendritic cells. Read more.

Surgical Maneuvers

Femtosecond laser assists implantation of miniature telescope

A surgeon describes cataract surgery coupled with placement of the Implantable Miniature Telescope for AMD. Read more.

By the Numbers

Here we go again: 20 early recession-proofing actions to take now to help your practice

The business cycle is the rhythmic rise and fall of economic growth that occurs over time. This cycle is a useful tool for understanding the economy. It can also help you make better practice and personal financial decisions, even if you are not an economist. Read more.

Challenges in Ophthalmology with April Steinert

Outgoing ASCRS executive director challenged by overregulation in ophthalmology

David Karcher explains how government restrictions have created frustrations for ASCRS members. Read more.